Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus.
about
Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practiceA Retrospective Comparison of Taxane and Fluorouracil-based Chemoradiotherapy in Patients with Inoperable Esophageal Squamous Cell Carcinoma.Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinomaPredictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastasis alone.Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.Management and outcomes of localized esophageal and gastroesophageal junction cancer in older patients.VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinomaRecombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus.Definitive chemoradiation in patients with inoperable oesophageal carcinoma.Treatment of thoracic esophageal carcinoma invading adjacent structures.Involved-field irradiation in definitive chemoradiotherapy for T4 squamous cell carcinoma of the esophagusChemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives.TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.Multimodal treatment strategy for clinical T3 thoracic esophageal cancer.Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan.Outcome for esophageal cancer following treatment with chemotherapy and radiotherapy but not esophagectomy: Nonsurgical treatment of esophageal cancer.Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study.Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer.Surveillance or resection after chemoradiation in esophageal cancer.Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy.Clinical results of multimodality therapy for esophageal cancer with distant metastasis.
P2860
Q28073933-8699E0AC-40D3-4A8C-9F8B-E2F8A09AE7E8Q33433296-F1DA295E-042D-4786-B1BB-699C9A236B54Q33646186-A404788F-3AF5-4B66-9F7B-D138FCFB7CF2Q33866015-6A07F31B-A2EB-4913-8970-723AAE8DD5DAQ34043755-DE3706EF-C571-4517-AE31-D00223C67455Q34610991-26E778F5-A8A1-4318-8E3D-C8A8E767ACCAQ35420526-48D2988A-E56A-429E-ADB8-26A4A25970C2Q35538453-7DBC4AB1-D9B6-4B7B-BA7D-4DD49D5138DCQ36378181-84CB53F1-FC68-4A97-B5A5-AA789353F2ECQ36394599-C6647004-D83E-4282-AFDB-CDAD40BC5433Q36400850-EC8010EC-6D86-49BF-A33D-2F6E7A987DEEQ36407099-ECBA22D0-4F3E-4B48-8A9E-FC31AFE72A75Q36673737-8665E8AE-61DB-4F56-8D91-76009E36DDBCQ36794837-BFEE3742-A9A9-4B42-85A5-9414FFD789DFQ36807919-7526903E-601A-49E6-889A-99DE99D4FA45Q37198610-45530C3F-7ECB-4F6F-81E7-4388E1BC0851Q37246100-F885712E-C108-43DD-A839-8988B292F167Q37376917-B0B48EED-11CD-4ACD-B03E-4AC757D60E91Q37605384-868CAEF7-03AD-455D-98A2-4E9334764ADDQ38128743-9E2A71BF-80FC-49EE-8F9A-34DA684235FEQ38367708-9E40ED94-3241-4146-927D-7E3D6568F1ABQ38577792-4102BAA7-C9D3-4207-8190-F42B3702826FQ42731854-0C9ABAC3-5567-41B5-80ED-F9F780E7B292Q46281811-DFF3728D-794D-4B78-99B0-21A6C7AE12A2Q47104240-977580E8-3A02-4426-962D-192938FDE3CAQ53073167-E4BEB641-6FBA-4202-B102-33FD09FC1CF5Q53138654-AF3292CC-B9DB-47AE-B399-852202152AF5Q55445604-14F8C354-039B-46C8-B8C7-A8DFCDC4D9B8
P2860
Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Definitive chemoradiotherapy f ...... l carcinoma of the oesophagus.
@ast
Definitive chemoradiotherapy f ...... l carcinoma of the oesophagus.
@en
type
label
Definitive chemoradiotherapy f ...... l carcinoma of the oesophagus.
@ast
Definitive chemoradiotherapy f ...... l carcinoma of the oesophagus.
@en
prefLabel
Definitive chemoradiotherapy f ...... l carcinoma of the oesophagus.
@ast
Definitive chemoradiotherapy f ...... l carcinoma of the oesophagus.
@en
P2093
P2860
P356
P1476
Definitive chemoradiotherapy f ...... l carcinoma of the oesophagus.
@en
P2093
A Katagiri
K Mitamura
T Kitahara
T Kurahashi
T Yamamoto
P2860
P2888
P356
10.1038/SJ.BJC.6600684
P407
P577
2003-01-01T00:00:00Z